Travere Therapeutics, Inc.
(NASDAQ : RTRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 1.23%165.210.7%$1347.04m
LLYEli Lilly & Co. 1.28%325.661.1%$1081.34m
ABBVAbbVie, Inc. 1.87%140.901.9%$868.16m
PFEPfizer Inc. 0.95%44.560.9%$805.75m
BMYBristol-Myers Squibb Co. 1.30%71.451.0%$782.75m
MRKMerck & Co., Inc. 0.71%88.170.7%$715.40m
AZNAstraZeneca Plc 2.00%56.661.0%$395.24m
ALNYAlnylam Pharmaceuticals, Inc. -0.66%195.498.2%$215.95m
GSKGSK Plc 2.05%30.870.3%$213.95m
NVSNovartis AG 1.87%78.110.2%$205.45m
GBTGlobal Blood Therapeutics, Inc. -0.01%68.485.4%$191.16m
IDXXIDEXX Laboratories, Inc. 3.21%347.473.9%$190.19m
HZNPHorizon Therapeutics Plc 1.45%65.195.4%$176.16m
ATXIAvenue Therapeutics, Inc. 22.76%14.130.0%$171.02m
SRPTSarepta Therapeutics, Inc. 0.55%110.5412.4%$137.48m

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.